Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study

<p>Abstract</p> <p>Background</p> <p>In patients with relapsing–remitting multiple sclerosis (RRMS), subcutaneous (sc) interferon (IFN)β-1a and IFNβ-1b have been shown to reduce relapse rates. A formulation of IFNβ-1a has been produced without fetal bovine serum and wit...

Full description

Bibliographic Details
Main Authors: Singer Barry, Bandari Daniel, Cascione Mark, LaGanke Christopher, Huddlestone John, Bennett Randy, Dangond Fernando
Format: Article
Language:English
Published: BMC 2012-12-01
Series:BMC Neurology
Subjects:
Online Access:http://www.biomedcentral.com/1471-2377/12/154